Company intelligence / Profile preview

Mursla Bio

Cambridge, England, United Kingdommursla.com ↗

Ownership: Private
Employees: ~17
Development stage: Other

Overview

EvoLiver™, the company’s flagship blood-based test for early liver cancer detection, demonstrated an early-stage sensitivity of 86% at a specificity of 88% among cirrhotic high-risk patients. The test recently received FDA Breakthrough Device Designation. Additional peer-reviewed clinical data are expected later this year.

Therapeutic areas: Oncology
Modalities: Diagnostic device (liquid biopsy)AI-enabled multiomic profiling platformExtracellular vesicle-based diagnosticsIn vitro diagnostic assay
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Mursla Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mursla Bio.

Explore the full profile